OnKure Therapeutics
OKUR
42 hedge funds and large institutions have $28.1M invested in OnKure Therapeutics in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 8 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
9% more capital invested
Capital invested by funds: $25.8M → $28.1M (+$2.34M)
4.48% less ownership
Funds ownership: 84.06% → 79.57% (-4.5%)
14% less funds holding
Funds holding: 49 → 42 (-7)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
88% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Shay Capital
New York
|
+$337K |
| 2 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$311K |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$268K |
| 4 |
Renaissance Technologies
New York
|
+$132K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$92.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
-$832K |
| 2 |
CF
Cantor Fitzgerald
New York
|
-$440K |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$431K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$180K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$131K |
OKUR Hedge Fund Activity: Q3 2025 in Review
42 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q3 2025, worth a combined $28.1M — up 9.1% from $25.8M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of OKUR and 1 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 15 added.
The largest buyer was Shay Capital, adding an estimated $337K. The largest seller was Affinity Asset Advisors, exiting entirely with an estimated $832K sold.
- 42 institutional investors held OnKure Therapeutics (OKUR) as of Q3 2025, down from 49 in Q2 2025.
- Funds reported $28.1M of OnKure Therapeutics stock for Q3 2025, up 9.1% quarter-over-quarter.
- 1 fund opened new OnKure Therapeutics positions in Q3 2025 and 8 closed out, a net change of -7 holders.
- The largest OnKure Therapeutics buyer in Q3 2025 was Shay Capital, an estimated $337K added.
- The largest OnKure Therapeutics seller in Q3 2025 was Affinity Asset Advisors, an estimated $832K sold.
Based on aggregated 13F filings for Q3 2025.